Cartalax

Cartalax is supplied as a laboratory research reference material intended solely for in-vitro and laboratory research use. The item is a synthetic short-chain tripeptide corresponding to the free-acid sequence Ala-Glu-Asp (single-letter AED), assembled from three proteinogenic L-amino-acid residues joined by two standard alpha-peptide bonds. It is registered under CAS 1247113-86-1, with the molecular formula C12H20N4O8 and a monoisotopic-consistent average molecular weight of 332.31 g/mol.

Structurally, Cartalax presents an N-terminal alanine bearing a free primary amine, an internal glutamic-acid residue contributing a pendant gamma-carboxyl side chain, and a C-terminal aspartic-acid residue whose beta-carboxyl and terminal alpha-carboxyl together give the molecule its characteristic acidic, polyanionic character at neutral pH. The two side-chain carboxylates plus the terminal carboxyl and free N-terminus produce a low theoretical isoelectric point and high aqueous solubility, which is a useful reference point for analysts developing ion-exchange, reversed-phase, or HILIC separations against this scaffold.

Physically, Cartalax is offered as a white to off-white lyophilized powder from synthetic origin (catalog SKU: CARTALAX), with 3 residues in the sequence Ala-Glu-Asp. Purity is specified as not less than 98% by HPLC, with lot-specific identity and purity data (typically including RP-HPLC chromatograms and mass-spectrometric confirmation consistent with the 332.31 g/mol target) documented on the Certificate of Analysis available on request. The lyophilized format supports controlled reconstitution in the researcher’s chosen laboratory buffer system for characterization, method development, calibration, and comparative analytical work.

Published scientific literature has examined Cartalax in preclinical research contexts, and the material is offered here strictly as a chemical reference standard to support such investigative and analytical workflows. PEPTIDE.Power makes no therapeutic, diagnostic, or efficacy claims regarding Cartalax and provides no administration or dosing guidance of any kind. This material is not a drug, supplement, cosmetic, or food, and is not intended for human or veterinary use, injection, or ingestion. All handling, storage, and experimental use are the responsibility of the qualified receiving laboratory.